婴儿血瘤的儿童在兰醇治疗期间的血小板聚合反应
Havva Özüm Kolsuz1, Zeynep Canan Özdemir2, Özcan Bör2
1Eskişehir Osmangazi University, Faculty of Medicine, Department of Pediatrics.
概括
普罗普拉诺洛尔有效治疗儿童的婴儿血瘤,在一个月内减少大小并改善外观. 重要的是,这种治疗没有对血液细胞计数或血小板聚合产生负面影响.
科学领域:
- 儿科皮肤病学 儿科皮肤病学
- 血管异常 血管异常
- 药理学 药理学是指药理学的学科.
背景情况:
- 婴儿血瘤涉及不成熟的内皮细胞增殖.
- 虽然往往会自发地消失,但有些病例需要治疗.
- β抑制剂是一种治疗选择,但存在关于血小板聚合的担忧.
研究的目的:
- 评估普拉诺洛尔在治疗婴儿血管瘤中的疗效和安全性.
- 为了评估血管瘤大小,外观,血清和血小板聚合的变化.
主要方法:
- 一项研究包括了20名患有婴儿血瘤的儿童,这些儿童接受了普罗兰诺洛尔 (1毫克/千克/天) 治疗.
- 血液瘤特征,血细胞计数和血小板聚合 (通过光传导聚合计) 在治疗前和一个月后进行了比较.
- 还包括一个由20名健康儿童组成的对照组.
主要成果:
- 普罗兰醇显著减少了婴儿血管瘤的大小 (平均2.46厘米与2.65厘米),并且在26.1%的病例中改善了外观.
- 在68.4%的患者中,胀减少.
- 没有观察到血清参数或血小板聚合反应的显著变化.
结论:
- 普罗普拉诺洛尔 (1毫克/公斤/天) 是一个有效的治疗婴儿血管瘤一个月后.
- 治疗对血瘤的大小和外观产生了积极影响.
- 在儿科患者中,普罗普兰诺洛没有对血细胞计数或血小板聚合产生不利影响.
相关概念视频
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
648
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
648
Formation of the Platelet Plug
7.1K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
7.1K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
257
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
257
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
995
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
995
Introduction to Hemostasis
8.9K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
8.9K
Clot Retraction and Fibrinolysis
6.9K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.9K


